AMENDMENTS TO THE CLAIMS:

Amend the claims as follows:

Claim 1-61. (Canceled)

62. (Currently Amended) A compound of the formula:



(1)

wherein:

J is a linking functional group and is independently:

-C(=O)- or -O-C(=O)- or -C(=O)-O-;

Cy is a cyclyl group and is independently:

C_{3-20}carbocyclyl, C_{3-20}heterocyclyl, or C_{5-20}aryl;

and is optionally substituted;

Q^1 is a cyclyl leader group, and is independently a divalent bidentate group obtained by removing two hydrogen atoms from a ring carbon atom of a saturated monocyclic hydrocarbon having from 4 to 7 ring atoms, or by removing two hydrogen atoms from a ring carbon atom of saturated monocyclic heterocyclic compound having from 4 to 7 ring atoms including 1 nitrogen ring atom or 1 oxygen ring atom; and is optionally substituted;

If J is –O-C(=O)- or C(=O)-O-, then:

Q^2 is an acid leader group, and is independently:

C_{1-8}alkylene;

and is optionally substituted;

or:

Q^2 is an acid leader group, and is independently:

C_{5-20}arylene;

C_{5-20}arylene-C_{1-7}alkylene;

C_{1-7}alkylene-C_{5-20}arylene; or,

C_{1-7}alkylene-C_{5-20}arylene-C_{1-7}alkylene;

and is optionally substituted;

if J is -C(=O)-, then:

Q^2 is an acid leader group, and is independently:

C_{5-20}arylene;

C_{5-20}arylene-C_{1-7}alkylene;

C_{1-7}alkylene-C_{5-20}arylene; or,

C_{1-7}alkylene-C_{5-20}arylene-C_{1-7}alkylene;

and is optionally substituted;

and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.

63. (Previously Presented) A compound according to claim 62, wherein J is -O-C(=O)- or -C(=O)-O-.

64. (Previously Presented) A compound according to claim 62, wherein J is -O-C(=O)-.

65. (Previously Presented) A compound according to claim 62, wherein J is -C(=O)-O-.

66. (Previously Presented) A compound according to claim 62, wherein J is -C(=O)-.

67. (Previously Presented) A compound according to claim 62, wherein Q^1 is independently a group of the formula:



wherein:

the ring independently has from 4 to 7 ring atoms;

Z is independently $-CH_2-$, $-N(R^N)-$ or -O-;

R^N, if present, is independently -H, C_{1-7}alkyl, C_{5-20}aryl-C_{1-7}alkyl, C_{3-20}heterocyclyl, or C_{5-20}aryl; and

Q^1 is optionally further substituted.

68. (Previously Presented) A compound according to claim 67, wherein Q^1 is independently a group of the formula:



wherein y is independently 1, 2, 3, or 4.

69. (Previously Presented) A compound according to claim 68, wherein Q^1 is independently selected from:





70. (Previously Presented) A compound according to claim 69, wherein Q^1 is independently:



71. (Previously Presented) A compound according to claim 69, wherein Q^1 is independently:



72. (Previously Presented) A compound according to claim 69, wherein Q^1 is independently:



73. (Previously Presented) A compound according to claim 67, wherein R^N, if present, is independently selected from: -H, -Me, -Et, -Ph, and -CH_2-Ph.

74. (Previously Presented) A compound according to claim 67, wherein R^N, if present, is independently -H.

75. (Previously Presented) A compound according to claim 62, wherein substituents on Q^1, if present, are independently selected from:

-F, -Cl, -Br, -I, -OH, -OMe, -OEt, -O(iPr), -Ph, -C(=O)Me, $-NH_2$, $-NMe_2$, $-NEt_2$, morpholino, $-CONH_2$, $-CONMe_2$, -NHCOMe, and =O;

and wherein, if a substituent is on an arylene group , it may additionally be selected from: -Me, -Et, -iPr, -tBu, $-CF_3$.

76. (Previously Presented) A compound according to claim 62, wherein Cy is independently C_{3-20}carbocyclyl; and is optionally substituted.

77. (Previously Presented) A compound according to claim 62, wherein Cy is independently C_{3-20}heterocyclyl; and is optionally substituted.

78. (Previously Presented) A compound according to claim 62, wherein Cy is independently C_{5-20}aryl; and is optionally substituted.

79. (Previously Presented) A compound according to claim 62, wherein Cy is independently C_{5-20}carboaryl or C_{5-20}heteroaryl; and is optionally substituted.

80. (Previously Presented) A compound according to claim 62, wherein Cy is independently C_{5-20}aryl derived from one of the following:

benzene, pyridine, furan, indole, pyrrole, imidazole, naphthalene, quinoline, benzimidazole, benzothiofuran, fluorene, acridine, and carbazole; and is optionally substituted.

81. (Previously Presented) A compound according to claim 62, wherein Cy is independently C_{5-20}aryl derived from benzene and is optionally substituted.

82. (Previously Presented) A compound according to claim 62, wherein Cy is independently an optionally substituted phenyl group of the formula:



wherein n is independently an integer from 0 to 5, and

each R^A is independently a substituent.

83. (Previously Presented) A compound according to claim 82, wherein n is 0.

84. (Previously Presented) A compound according to claim 82, wherein n is 1, and the R^A group is in the 4'-position.

85. (Previously Presented) A compound according to claim 82, wherein n is 2, and one R^A group is in the 4'-position, and the other R^A group is in the 2'-position.

86. (Previously Presented) A compound according to claim 82, wherein n is 2, and one R^A group is in the 4'-position, and the other R^A group is in the 3'-position.

87. (Previously Presented) A compound according to claim 62, wherein each of the substituents on Cy, if present, is independently selected from:

(1) ester;

(2) amido;

(3) acyl;

(4) halo;

(5) hydroxy;

(6) ether;

(7) C_{1-7}alkyl; substituted C_{1-7}alkyl;

(8) C_{5-20}aryl; substituted C_{5-20}aryl;

(9) sulfonyl;

(10) sulfonamido.

88. (Previously Presented) A compound according to claim 62, wherein each of the substituents on Cy, if present, is independently selected from:

(1) -C(=O)OR^1, wherein R^1 is independently C_{1-7}alkyl as defined in (7);

(2) -C(=O)NR^2R^3, wherein each of R^2 and R^3 is independently -H or C_{1-7}alkyl as defined in (7);

(3) -C(=O)R^4, wherein R^4 is independently C_{1-7}alkyl as defined in (7) or C_{5-20}aryl as defined in (8);

(4) -F, -Cl, -Br, -I;

(5) -OH;

(6) -OR^5, wherein R^5 is independently C_{1-7}alkyl as defined in (7) or C_{5-20}aryl as defined in (8);

(7) C_{1-7}alkyl; substituted C_{1-7}alkyl;

halo-C_{1-7}alkyl;

amino-C_{1-7}alkyl;

carboxy-C_{1-7}alkyl;

hydroxy-C_{1-7}alkyl;

C_{1-7}alkoxy-C_{1-7}alkyl;

C_{5-20}aryl-C_{1-7}alkyl;

(8) C_{5-20}aryl; substituted C_{5-20}aryl;

(9) -SO_2R^7, wherein R^7 is independently C_{1-7}alkyl as defined in (7) or C_{5-20}aryl as defined in (8);

(10) $-SO_2NR^8R^9$, wherein each of R^8 and R^9 is independently -H or C_{1-7}alkyl as defined in (7).

89. (Previously Presented) A compound according to claim 62, wherein each of the substituents on Cy, if present, is independently selected from:

(1) -C(=O)OMe, -C(=O)OEt, -C(=O)O(Pr), -C(=O)O(iPr), -C(=O)O(nBu), -C(=O)O(sBu), -C(=O)O(iBu), -C(=O)O(tBu), -C(=O)O(nPe);

$-C(=O)OCH_2CH_2OH$, $-C(=O)OCH_2CH_2OMe$, $-C(=O)OCH_2CH_2OEt$;

(2) $-(C=O)NH_2$, $-(C=O)NMe_2$, $-(C=O)NEt_2$, $-(C=O)N(iPr)_2$, $-(C=O)N(CH_2CH_2OH)_2$;

(3) -(C=O)Me, -(C=O)Et, -(C=O)-cHex, -(C=O)Ph;

(4) -F, -Cl, -Br, -I;

(5) -OH;

(6) -OMe, -OEt, -O(iPr), -O(tBu), -OPh;

$-OCF_3$, $-OCH_2CF_3$;

$-OCH_2CH_2OH$, $-OCH_2CH_2OMe$, $-OCH_2CH_2OEt$;

$-OCH_2CH_2NH_2$, $-OCH_2CH_2NMe_2$, $-OCH_2CH_2N(iPr)_2$;

-OPh, -OPh-Me, -OPh-OH, -OPh-OMe, O-Ph-F, -OPh-Cl, -OPh-Br, -OPh-I;

(7) -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu, -nPe;

$-CF_3$, $-CH_2CF_3$;

$-CH_2CH_2OH$, $-CH_2CH_2OMe$, $-CH_2CH_2OEt$;

$-CH_2CH_2NH_2$, $-CH_2CH_2NMe_2$, $-CH_2CH_2N(iPr)_2$;

$-CH_2$-Ph;

(8) -Ph, -Ph-Me, -Ph-OH, -Ph-OMe, -Ph-F, -Ph-Cl, -Ph-Br, -Ph-I;

(9) $-SO_2Me$, $-SO_2Et$, $-SO_2Ph$;

(10) $-SO_2NH_2$, $-SO_2NMe_2$, $-SO_2NEt_2$.

90. (Previously Presented) A compound according to claim 62, wherein each of the substituents on Cy, if present, is independently selected from:

-C(=O)OMe, -OMe, -C(=O)Me, $-SO_2Me$, $-SO_2NMe_2$, $-C(=O)NH_2$, $-OCF_3$, and $-CH_2CH_2OH$.

91. (Previously Presented) A compound according to claim 62, wherein the acid leader group, Q^2, is independently:

C_{5-20}arylene;

and is optionally substituted.

92. (Previously Presented) A compound according to claim 62, wherein Q^2 is independently C_{5-6}arylene; and is optionally substituted.

93. (Previously Presented) A compound according to claim 62, wherein Q^2 is independently phenylene; and is optionally substituted.

94. (Previously Presented) A compound according to claim 93, wherein the phenylene linkage is meta or para.

95. (Previously Presented) A compound according to claim 93, wherein the phenylene linkage is meta.

96. (Previously Presented) A compound according to claim 93, wherein the phenylene linkage is para.

97. (Previously Presented) A compound according to claim 91, wherein Q^2 is independently unsubstituted.

98. (Currently Amended) A compound according to claim 62, wherein J is -O-C(=O)- or -C(=O)-O- and the acid leader group, Q^2, is independently:

C_{1-8}alkylene;

and is optionally substituted.

99. (Currently Amended) A compound according to claim 62, wherein J is -O-C(=O)- or -C(=O)-O- and Q^2 is independently:

(a) a saturated C_{1-7}alkylene group; or:

(b) a partially unsaturated C_{2-7}alkylene group; or:

(c) an aliphatic C_{1-7}alkylene group; or:

(d) a linear C_{1-7}alkylene group; or:

(e) a branched C_{2-7}alkylene group; or:

(f) a saturated aliphatic C_{1-7}alkylene group; or:

(g) a saturated linear C_{1-7}alkylene group; or:

(h) a saturated branched C_{2-7}alkylene group; or:

(i) a partially unsaturated aliphatic C_{2-7}alkylene group; or:

(j) a partially unsaturated linear C_{2-7}alkylene group; or:

(k) a partially unsaturated branched C_{2-7}alkylene group;

and is optionally substituted.

100. (Currently Amended) A compound according to claim 62, wherein J is -O-C(=O)- or -C(=O)-O- and Q^2 is independently selected from:

$-(CH_2)_5-$; $-(CH_2)_6-$; $-(CH_2)_7-$; and $-(CH_2)_8-$.

101. (Previously Presented) A compound according to claim 62, wherein Q^2 is independently:

C_{5-20}arylene-C_{1-7}alkylene;

C_{1-7}alkylene-C_{5-20}arylene; or,

C_{1-7}alkylene-C_{5-20}arylene-C_{1-7}alkylene;

and is optionally substituted.

102. (Previously Presented) A compound according to claim 62, wherein Q^2 is independently:

C_{5-6}arylene-C_{1-7}alkylene;

C_{1-7}alkylene-C_{5-6}arylene; or,

C_{1-7}alkylene-C_{5-6}arylene-C_{1-7}alkylene;

and is optionally substituted.

103. (Previously Presented) A compound according to any claim 62, wherein Q^2 is independently:

phenylene-C_{1-7}alkylene;

C_{1-7}alkylene-phenylene; or,

C_{1-7}alkylene-phenylene-C_{1-7}alkylene;

and is optionally substituted.

104. (Previously Presented) A compound according to claim 62, wherein Q^2 independently has a backbone of from 5 to 6 atoms.

105. (Previously Presented) A compound according to claim 62, wherein each of the substituents on Q^2, if present, is independently selected from:

halo, hydroxy, ether, C_{1-7}alkoxy, C_{5-20}aryl, acyl, amino, amido, acylamido, nitro, and oxo; and wherein, if a substituent is on an arylene group, it may additionally be selected from: C_{1-7}alkyl and substituted C_{1-7}alkyl.

106. (Previously Presented) A compound according to claim 62, wherein each of the substituents on Q^2, if present, is independently selected from:

-F, -Cl, -Br, -I, -OH, -OMe, -OEt, -O(iPr), -Ph, -C(=O)Me, $-NH_2$, $-NMe_2$, $-NEt_2$, morpholino, $-CONH_2$, $-CONMe_2$, -NHCOMe, $-NO_2$, and =O; and wherein, if a substituent is on an arylene group, it may additionally be selected from: -Me, -Et, -iPr, -tBu, $-CF_3$.

107. (Previously Presented) A compound of the formula:



(1)

wherein:

J is independently: -C(=O)-O-;

Q^1 is independently:



Q^2 is phenylene, and is optionally substituted;

Cy is phenyl, and is optionally substituted;

and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.

108. (Previously Presented) A compound selected from the following compounds, and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof:

1		PX118478

2		PX118479
3		PX118480
4		PX119101
5		PX118925

6		PX118926
7		PX118959
8		PX118966
9		PX119058

10		PX119059
11		PX119061
12		PX119062
13		PX119064

14		PX119065
15		PX119084
16		PX119100
17		PX119063

18		PX119085
19		PX119086
20		PX119102

21		PX119103
22		
23		
24		

109. (Previously Presented) A composition comprising a compound according to claim 62 and a pharmaceutically acceptable carrier.